Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BC 007 is a DNA-based aptamer designed to specifically target and neutralize functional autoantibodies (fAABs) directed against G-protein coupled receptors. It is being evaluated for the treatment of Long Covid.
Lead Product(s): BC 007
Therapeutic Area: Infections and Infectious Diseases Product Name: BC 007
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Berlin Cures Holding AG is evaluating BC 007, a β1-adrenoceptor autoantibody neutralizing ssDNA product, for the treatment of COVID-19. BC 007 consists of a synthetically produced short and unmodified aptamer, which is able to bind to the spike protein of the coronavirus..
Lead Product(s): BC007
Therapeutic Area: Infections and Infectious Diseases Product Name: BC007
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020